TORONTO, Oct. 6 /CNW/ - Theralase Technologies Inc. (TSX-V: TLT) today announced that it has delivered a TLC-3000 prototype PDC light system to University Health Network for the pre-clinical evaluation of Theralase's patented oxygen independent photodynamic compounds (PDCs) in the destruction of cancer, bacteria, viruses and fat cells.

The TLC-3000 PDC light system has been specifically designed to increase the activation of Theralase's PDCs, by optimizing both the wavelength and the power of the light delivered. The time for activation will now take a tenth of the time previously required. This significant breakthrough will ultimately result in a decrease in the treatment time to destroy a given cell type as well as an increase in the size of cancerous tumours that can be destroyed with the technology.

"We are pleased to be one step closer to the commercialization of our PDCs in the destruction of cancer, bacteria, viruses and fat cells," said Roger Dumoulin-White, President & CEO of Theralase Technologies. "Our unique platform of patented oxygen independent PDCs have the ability to destroy cancerous tumours in low oxygen environments that are not able to be destroyed by any other treatment methodology."

University Health Network demonstrated through trials earlier this year, that Theralase's patented PDCs have the ability to selectively target and destroy cancerous cells over cells derived from healthy tissue.

Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology used in a wide range of bio-stimulation and bio-destruction clinical applications. The Theralase technology platform targets several diverse healthcare sectors: firstly, for non-invasive pain management and clinical therapy, in hundreds of neural muscular skeletal conditions including arthritis; secondly, to bio-stimulate and accelerate wound care and healing including bone fracture regeneration; and thirdly, combining photodynamic compounds with super-pulsed, biofeedback laser technology to attack specifically targeted cancer, bacteria, viruses and fat cells.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the contents of this
release.